Research ExplorerPublicationsEfficacy of guselkumab in difficult-to-treat psoriasis regio...

Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations

Standard

Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations. / Jo, Seong Jin; Huang, Yu-Huei; Tsai, Tsen-Fang; Kim, Byung Soo; Reich, Kristian; Saadoun, Carine; Chang, Chia-Ling; Yang, Ya-Wen; Youn, Sang Woong.

In: J DERMATOL, Vol. 50, No. 9, 09.2023, p. 1180-1189.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Jo, SJ, Huang, Y-H, Tsai, T-F, Kim, BS, Reich, K, Saadoun, C, Chang, C-L, Yang, Y-W & Youn, SW 2023, 'Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations', J DERMATOL, vol. 50, no. 9, pp. 1180-1189. https://doi.org/10.1111/1346-8138.16865

APA

Jo, S. J., Huang, Y-H., Tsai, T-F., Kim, B. S., Reich, K., Saadoun, C., Chang, C-L., Yang, Y-W., & Youn, S. W. (2023). Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations. J DERMATOL, 50(9), 1180-1189. https://doi.org/10.1111/1346-8138.16865

Vancouver

Jo SJ, Huang Y-H, Tsai T-F, Kim BS, Reich K, Saadoun C et al. Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations. J DERMATOL. 2023 Sep;50(9):1180-1189. https://doi.org/10.1111/1346-8138.16865

Bibtex

@article{ba0ecc17ece24ca0973ca6ab2749e3c9,
title = "Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations",
abstract = "Patients with psoriasis were randomized to guselkumab, placebo or adalimumab in the VOYAGE 1 and VOYAGE 2 studies. In this post hoc analysis, difficult-to-treat psoriasis regions in the Asian subpopulation for both the guselkumab and adalimumab groups were compared with placebo at week 16 and the active treatment groups were compared at week 24. Endpoints included patients achieving scores of 0 or 1 (clear or near clear) or 0 (clear) on the scalp-specific Investigator's Global Assessment (ss-IGA), Physician's Global Assessment of the hands and/or feet (hf-PGA), and fingernail PGA (f-PGA), and percentage improvement in target Nail Psoriasis Severity Index (NAPSI) score through week 24. Efficacy was also assessed by prior biologic experience at baseline. A total of 199 eligible Asian patients were included. The proportion of patients achieving {"}clear{"} or {"}near clear{"} with guselkumab was superior to adalimumab at week 24 for scalp psoriasis ss-IGA (Asian patients, 72 [85.7%] vs 35 [67.3%], P = 0.004), hands and/or feet psoriasis hf-PGA (29 [82.9%] vs 16 [61.5%], P = 0.054), and similar for fingernail psoriasis f-PGA (28 [63.6%] vs 17 [54.8%], P = 0.412). Guselkumab mean improvements in NAPSI were comparable to adalimumab (39.9% vs 35.9%, P = 0.618). Overall, the complete clearance response of scalp, and hands and/or feet at week 24 occurred in a greater proportion of patients in the guselkumab group, irrespective of baseline biologic status (treatment-na{\"i}ve or treatment-experienced). Guselkumab was superior to adalimumab for the treatment of scalp, and hands and/or feet psoriasis, and proportionally higher for fingernail psoriasis. Findings were comparable to the global study population.",
keywords = "Humans, Adalimumab/therapeutic use, Antibodies, Monoclonal/therapeutic use, Severity of Illness Index, Double-Blind Method, Psoriasis/drug therapy, Nail Diseases/drug therapy, Biological Products/therapeutic use, Immunoglobulin A, Treatment Outcome",
author = "Jo, {Seong Jin} and Yu-Huei Huang and Tsen-Fang Tsai and Kim, {Byung Soo} and Kristian Reich and Carine Saadoun and Chia-Ling Chang and Ya-Wen Yang and Youn, {Sang Woong}",
note = "{\textcopyright} 2023 Japanese Dermatological Association.",
year = "2023",
month = sep,
doi = "10.1111/1346-8138.16865",
language = "English",
volume = "50",
pages = "1180--1189",
number = "9",

}

RIS

TY - JOUR

T1 - Efficacy of guselkumab in difficult-to-treat psoriasis regions: Data from VOYAGE 1 and VOYAGE 2 Asian subpopulations

AU - Jo, Seong Jin

AU - Huang, Yu-Huei

AU - Tsai, Tsen-Fang

AU - Kim, Byung Soo

AU - Reich, Kristian

AU - Saadoun, Carine

AU - Chang, Chia-Ling

AU - Yang, Ya-Wen

AU - Youn, Sang Woong

N1 - © 2023 Japanese Dermatological Association.

PY - 2023/9

Y1 - 2023/9

N2 - Patients with psoriasis were randomized to guselkumab, placebo or adalimumab in the VOYAGE 1 and VOYAGE 2 studies. In this post hoc analysis, difficult-to-treat psoriasis regions in the Asian subpopulation for both the guselkumab and adalimumab groups were compared with placebo at week 16 and the active treatment groups were compared at week 24. Endpoints included patients achieving scores of 0 or 1 (clear or near clear) or 0 (clear) on the scalp-specific Investigator's Global Assessment (ss-IGA), Physician's Global Assessment of the hands and/or feet (hf-PGA), and fingernail PGA (f-PGA), and percentage improvement in target Nail Psoriasis Severity Index (NAPSI) score through week 24. Efficacy was also assessed by prior biologic experience at baseline. A total of 199 eligible Asian patients were included. The proportion of patients achieving "clear" or "near clear" with guselkumab was superior to adalimumab at week 24 for scalp psoriasis ss-IGA (Asian patients, 72 [85.7%] vs 35 [67.3%], P = 0.004), hands and/or feet psoriasis hf-PGA (29 [82.9%] vs 16 [61.5%], P = 0.054), and similar for fingernail psoriasis f-PGA (28 [63.6%] vs 17 [54.8%], P = 0.412). Guselkumab mean improvements in NAPSI were comparable to adalimumab (39.9% vs 35.9%, P = 0.618). Overall, the complete clearance response of scalp, and hands and/or feet at week 24 occurred in a greater proportion of patients in the guselkumab group, irrespective of baseline biologic status (treatment-naïve or treatment-experienced). Guselkumab was superior to adalimumab for the treatment of scalp, and hands and/or feet psoriasis, and proportionally higher for fingernail psoriasis. Findings were comparable to the global study population.

AB - Patients with psoriasis were randomized to guselkumab, placebo or adalimumab in the VOYAGE 1 and VOYAGE 2 studies. In this post hoc analysis, difficult-to-treat psoriasis regions in the Asian subpopulation for both the guselkumab and adalimumab groups were compared with placebo at week 16 and the active treatment groups were compared at week 24. Endpoints included patients achieving scores of 0 or 1 (clear or near clear) or 0 (clear) on the scalp-specific Investigator's Global Assessment (ss-IGA), Physician's Global Assessment of the hands and/or feet (hf-PGA), and fingernail PGA (f-PGA), and percentage improvement in target Nail Psoriasis Severity Index (NAPSI) score through week 24. Efficacy was also assessed by prior biologic experience at baseline. A total of 199 eligible Asian patients were included. The proportion of patients achieving "clear" or "near clear" with guselkumab was superior to adalimumab at week 24 for scalp psoriasis ss-IGA (Asian patients, 72 [85.7%] vs 35 [67.3%], P = 0.004), hands and/or feet psoriasis hf-PGA (29 [82.9%] vs 16 [61.5%], P = 0.054), and similar for fingernail psoriasis f-PGA (28 [63.6%] vs 17 [54.8%], P = 0.412). Guselkumab mean improvements in NAPSI were comparable to adalimumab (39.9% vs 35.9%, P = 0.618). Overall, the complete clearance response of scalp, and hands and/or feet at week 24 occurred in a greater proportion of patients in the guselkumab group, irrespective of baseline biologic status (treatment-naïve or treatment-experienced). Guselkumab was superior to adalimumab for the treatment of scalp, and hands and/or feet psoriasis, and proportionally higher for fingernail psoriasis. Findings were comparable to the global study population.

KW - Humans

KW - Adalimumab/therapeutic use

KW - Antibodies, Monoclonal/therapeutic use

KW - Severity of Illness Index

KW - Double-Blind Method

KW - Psoriasis/drug therapy

KW - Nail Diseases/drug therapy

KW - Biological Products/therapeutic use

KW - Immunoglobulin A

KW - Treatment Outcome

U2 - 10.1111/1346-8138.16865

DO - 10.1111/1346-8138.16865

M3 - SCORING: Journal article

C2 - 37341137

VL - 50

SP - 1180

EP - 1189

IS - 9

ER -